Quick Roundup: This Week in Optimized Performance

1. FDA Fast-Tracks NMN: NAD+ Boosters Enter Regulatory Approval Pipeline

The FDA has granted fast-track review status to NMN (nicotinamide mononucleotide) as an NAD+ booster, following petitions from Elysium Health. This marks the first NAD+ precursor to receive regulatory pathway consideration since the 2022 supplement ban scare. NAD+ depletion is a fundamental hallmark of aging, and boosting intracellular levels has shown promise in extending healthspan across animal models. Human trial data continues to accumulate, with the TAME (Targeting Aging with Metformin) initiative advancing toward its goal of obtaining FDA approval for aging as an indications. ¹

2. Exosome Therapy Migrates from Clinic to Consumer: 2026 Regenerative Renaissance

Exosome therapy—the use of microscopic extracellular vesicles for tissue repair and cellular signaling—is transitioning from boutique regenerative medicine clinics to mainstream aesthetic and performance applications. Instagram posts from biohacking conferences indicate exponential growth in exosome treatments for hair restoration, skin rejuvenation, and recovery protocols. Vegan, plant-derived exosome alternatives have emerged as ethical alternatives to placental biologics, with new formulations marketed as needle-free skin boosters. The mechanism: exosomes deliver mRNA signals that trigger cellular regeneration without the controversy of stem cell treatments. ²

3. Molecular Hydrogen Clinics Proliferate: Inhalation, Infusion, and Water Protocols

Molecular hydrogen (H2) is emerging as the next big thermal therapy modality, with hydrogen inhalation clinics and H2-water protocols gaining traction in biohacking communities. Social media trends show hydrogen clinics, devices, and protocols appearing across wellness platforms in 2026. Research suggests H2 acts as a selective antioxidant, neutralizing harmful reactive oxygen species while preserving beneficial signaling molecules. Early adopters report benefits for recovery, inflammation reduction, and cognitive clarity, though human trial data remains preliminary. ³

4. Biohacking Market Hits $28.5B: AI Wearables Drive Growth

The global biohacking market reached $28.5 billion in 2025, representing 12% year-over-year growth driven by AI-integrated wearables and personalized optimization devices. Statista data confirms the sector's resilience amid economic headwinds. Crypto-linked biohacking tokens (e.g., HACK) surged 8% in early March, coinciding with Bitcoin rallies. The convergence of continuous glucose monitoring, HRV tracking, and AI-driven personalized recommendations represents the maturation of quantified self from hobbyist pursuit to mainstream consumer category. ⁴

5. FocusMax, Memopezil, and the Nootropic Arms Race Continue

The nootropic supplement market continues its fragmentation, with new entrants like FocusMax, Memopezil, and Mind Vault competing for cognitive enhancement share. Consumer research reports highlight ingredient-level research (Bacopa monnieri, Rhodiola rosea, Huperzine A) while noting gaps between marketing claims and product-level clinical evidence. The trend toward "natural donepezil alternatives" for acetylcholine support reflects aging demographics seeking cognitive preservation without pharmaceutical intervention. Transparency in proprietary blend dosing remains a consumer concern across the category. ⁵

Next deep dive: Tuesday, March 17, 2026